Red Star News Network (reporter Li Huiying) reported on April 12 that on April 12, the world's first clinical research on the treatment of periodontal disease by dental vesicle stem cells was launched in Chengdu, Sichuan Province, attracting many attention. It is understood that stem cell therapy has become the most cutting-edge and most promising research direction in periodontal disease research. The launch of the "world's first clinical research on the treatment of periodontal disease by dental vesicle stem cells" is not only a milestone breakthrough in periodontal disease treatment, but also a landmark event in China's stem cell industry, which means that the use of dental capsule stem cells for periodontal disease treatment can be expected in the future.
It is worth mentioning that a start-up called Chengdu Shilian Kangjian Biotechnology Co., Ltd. has played an important role in it. What kind of business is this? What are the cutting-edge technologies? Today, at the "World's First Clinical Research Project Briefing on the Treatment of Periodontal Disease" held at the Frontier Medical Center of Xinchuan Innovation and Technology Park in Chengdu High-tech Zone, the mystery of Shilian Health was unveiled.
Backed by West China The founding team is strong
According to public information, Shilian Health was jointly invested by the chengdu high-tech zone government, Chengdu West China Cell Therapy Research Institute Co., Ltd. (West China Hospital), Sichuan West China Maternal and Child Health Technology Co., Ltd. (West China Second Hospital), Sichuan West China Oral Health Technology Co., Ltd. (West China Stomatological Hospital), Shanghai Pharmaceutical Group, the national "973" and the chief scientist of the key research and development program, Professor Tian Weidong, and the team of Professor Tian Weidong, the chief scientist of the national "973" and key research and development programs, with a deep "background".
Among them, As an executive director and chief scientist, Tian Weidong is the industry benchmark leader, with 38 years of clinical work experience and more than 20 years of scientific research achievements in the field of stem cells and regenerative medicine, and is currently a second-level professor of Sichuan University, a doctoral supervisor, and the chief scientist of the national "973" and key research and development program projects.
The other founding team members are also professionals who have been working in the industry for many years and have many years of stem cell research experience or industry experience. The team has been immersed in stem cell and regenerative medicine research for more than 20 years, and has made a number of basic theoretical breakthroughs and technological innovations in the fields of odontogenic stem cells and adipose stem cells.
The strong strength of the team, coupled with the backing of West China, makes World Union Health not only have the qualifications and status of legal compliance, but also has a first-mover advantage in core technology and industry layout.
Independent research and development strive to fill the gap of stem cell drugs in China
As the leader of the stem cell industry in Sichuan, From the beginning of its establishment, Shilian Kangjian has been committed to building a world-class high-standard cell technology and cell drug research and development and transformation application platform in Chengdu Frontier Medical Center, and the world's first allogeneic human dental vesicle stem cell preparation independently developed by it has passed the quality review and inspection of the Three Batches of the Central Inspection Institute of the State Food and Drug Administration, and has been successfully filed with the National Health Commission in 2022. At present, together with west China Stomatological Hospital of Sichuan University and Peking University Stomatological Hospital, the world's first clinical research on the treatment of periodontal disease by allogeneic dental vesicle stem cells is launched, and strives to fill the gap of stem cell drugs in China.
At the same time, the company will carry out cell drug research and development and clinical treatment technology transformation in the direction of spinal cord injury repair, premature ovarian failure, knee injury, biological root regeneration, etc., and actively promote the clinical research of stem cells for other diseases, and the pipeline products of biomedical beauty and oral regeneration will also be industrialized.
The phase has a clear goal and has built one library and two centers
In order to build a world-class, high-standard cell technology and cell drug research and development and transformation application platform, and consolidate the major scientific infrastructure for the innovation and development of the biomedical field in the mainland, Shilian Kangjian has established a subsidiary Sichuan Cell Bank Co., Ltd. and Sichuan Tianfu Cell Quality Testing and Evaluation Center Co., Ltd., and established a cell industry innovation and development platform of "one library and two centers", namely cell information resource library, regional cell preparation center, cell quality testing and evaluation center, and laying out scarce resources in the field of stem cells.
Tian Weidong
Tang Yingfeng, director and deputy general manager of Shilian Kangjian and general manager of Sichuan Cell Bank Co., Ltd., introduced that Professor Tian Weidong, the founder and chief scientist of the platform, has devoted more than 20 years of research to the field of stem cells and regenerative medicine, and established the National Joint Local Engineering Laboratory of Oral Regeneration and the Engineering Research Center of the Ministry of Education, laying a solid foundation for stem cell drug and technology research and development, company construction and achievement transformation. At present, the overall project Phase I has completed the construction of a 3500-square-meter platform, including a national cell information resource library, a regional cell preparation center (adult stem cells, iPS cells and immune cell preparation) in six independent cell production workshops that meet the "B+A" cleanliness standard, and a sichuan Tianfu cell quality testing and evaluation center. Among them, the public technology platform for stem cell technology research and application and the integrated cell bank/regional cell preparation center became the first government certification body. At present, the company has initially formed a quality system that can be traced from the whole cycle of cell preparation, detection and storage, and a one-stop cell industry platform for the whole chain integrating medicine, teaching, research and production. On the basis of existing resources and platforms, it will build a high-tech biotechnology enterprise featuring precision medicine and precision health, integrating cell technology research and development, achievement transformation, technical services and talent training. ”
The reporter came to the Shilian Kangjian office building located in Chengdu Frontier Medical Center, and the outer side of the first floor can see rows of automated cell storage tanks through the glass, "Here is the Sichuan Provincial Cell Bank, as a national cell information resource library, it can provide tens of millions of copies of cell storage." Tang Yingfeng, deputy general manager of World Union Health, said. After changing into a white coat and putting on a disposable shoe cover, the reporter, under the leadership of the staff, entered the cell preparation center, cell testing center, cell cultivation laboratory and other floors to visit. Researchers in white coats in the workshop are busy with high-end instrumentation, and cells are being prepared.
Tang Yingfeng revealed that around the major national development strategy and major scientific and technological innovation needs in the field of stem cells, Shilian Kangjian will collect and prepare 20 kinds of clinical stem cell resources and 30 kinds of scientific research stem cell resources within 6 years, and build a strategic resource bank of adult stem cells with huge reserves of mainland stem cells.
At the same time, the company will be based on the national cell resource library in the future, cell preparation center and cell testing center as the condition, cell large-scale preparation GMP platform, cell quality detection public service platform, cell clinical transformation platform and other three major platforms as the goal, cell production standardization, cell drug quality evaluation, cell technology innovation, cell therapy clinical research services four major systems as the results, and finally built the "one library, two centers, three platforms and four systems" industrial layout, and actively promote the advent of stem cell drugs and treatment technology.
"We will base ourselves in Chengdu, face Yunnan, Guizhou, Sichuan and Chongqing, and radiate all over China." Build a one-stop innovation incubation and achievement transformation demonstration base for the biomedical industry, promote the healthy development of the transformation and application of the mainland stem cell resource industry, and further enhance the mainland's independent innovation ability in the field of stem cell transformation research. Tang Yingfeng said.